Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 2/20 | 0.41 |
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.41 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28916296 | 0.98 | KMT2A (0.49) | KMT2AMEN1L3MBTL1GLAALDH1A1 | |
| Potassium Ion SCHEMBL190393 | 0.96 | KMT2A (0.50) | KMT2AMEN1L3MBTL1GLAALDH1A1 | |
| SCHEMBL5492632 | 0.96 | KMT2A (0.50) | KMT2AMEN1L3MBTL1GLAALDH1A1 | |
| SCHEMBL29463334 | 0.91 | KMT2A (0.44) | KMT2AMEN1L3MBTL1GLAALDH1A1 | |
| SCHEMBL161682 | 0.88 | KEAP1 (0.48) | KMT2AMEN1L3MBTL1GLAALDH1A1 | |
| Hydrochloric Acid SCHEMBL30888463 | 0.86 | KEAP1 (0.47) | KMT2AMEN1L3MBTL1GLAKEAP1 | |
| SCHEMBL4455864 | 0.84 | ALOX15 (0.42) | KMT2AMEN1ALDH1A1SMN1; SMN2KDM4E | |
| Potassium Ion SCHEMBL9673910 | 0.84 | KEAP1 (0.48) | KMT2AMEN1L3MBTL1GLAALDH1A1 | |
| SCHEMBL4022653 | 0.84 | KEAP1 (0.48) | KMT2AMEN1L3MBTL1GLAALDH1A1 | |
| Water SCHEMBL9983319 | 0.82 | MAPT (0.40) | KMT2AMEN1L3MBTL1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1985 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589187-B2 | Valve material with combined anti-clotting and anti-calcification properties and preparation method | JILIN VENUS HAOYUE MEDICAL LIMITED (CN) | 2026-03-31 | — | — | US | claimed |
| US-20250249002-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL WOUND TREATMENT | CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECN (AR) | 2025-08-07 | — | — | US | claimed |
| EP-3870331-B1 | MODIFICATION OF ANTIBODY FCRN BINDING | HOFFMANN LA ROCHE (CH) | 2025-07-23 | — | — | EP | claimed |
| CN-115210324-B | Coloring composition and color filter | DIC株式会社 | 2025-02-21 | — | — | CN | claimed |
| CN-118531088-A | Blood microorganism detection reagent and preparation method thereof | 南通辉星生物科技有限公司 | 2024-08-23 | — | — | CN | claimed |
| CN-118006125-A | Polyamic acid composition and modified polyamide acid | 比亚迪股份有限公司 | 2024-05-10 | — | — | CN | claimed |
| US-11858883-B2 | Method for recycling taurine mother liquor | QIANJIANG Yongan Phamaceutical CO., LTD. (CN) | 2024-01-02 | — | — | US | claimed |
| CN-117233375-A | Kit for coupling fluorescent coding microsphere and antigen and application thereof | 深圳市亚辉龙生物科技股份有限公司 | 2023-12-15 | — | — | CN | claimed |
| US-20230218803-A1 | Valve Material With Combined Anti-Clotting And Anti-Calcification Properties And Preparation Method Therefor | JILIN VENUS HAOYUE MEDICAL LIMITED (CN) | 2023-07-13 | — | — | US | claimed |
| US-20230212111-A1 | METHOD FOR RECYCLING TAURINE MOTHER LIQUOR | QIANJIANG YONGAN PHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | US | claimed |
| WO-2019078197-A1 | HYPERPHOSPHATEMIA TREATMENT AGENT | 富士フイルム株式会社 | 2019-04-25 | — | — | WO | claimed |
| US-20120015044-A1 | FORMULATIONS FOR THE TREATMENT OF URUSHIOL-INDUCED CONTACT DERMATITIS | TREIBER, Laszlo (US) | 2012-01-19 | — | — | US | claimed |
| WO-2012009290-A2 | FORMULATIONS FOR THE TREATMENT OF URUSHIOL-INDUCED CONTACT DERMATITIS | TREIBER LASZLO (US) | 2012-01-19 | — | — | WO | claimed |
| EP-1272530-B1 | CLATHRATE COMPLEXES FORMED BY HYALURONIC ACID DERIVATIVES AND USE THEREOF AS PHARMACEUTICALS | FIDIA FARMACEUTICI (IT) | 2006-09-20 | — | — | EP | claimed |
| US-20040076680-A1 | Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals | SLOVAK ACADEMY OF SCIENCES (SK) | 2004-04-22 | — | — | US | claimed |
| EP-1272530-A1 | CLATHRATE COMPLEXES FORMED BY HYALURONIC ACID DERIVATIVES AND USE THEREOF AS PHARMACEUTICALS | FIDIA FARMACEUTICI S.p.A. (IT) | 2003-01-08 | — | — | EP | claimed |
| WO-2001066601-A1 | CLATHRATE COMPLEXES FORMED BY HYALURONIC ACID DERIVATIVES AND USE THEREOF AS PHARMACEUTICALS | FIDIA FARMACEUTICI S.P.A. (IT) | 2001-09-13 | — | — | WO | claimed |
| US-5567619-A | PRECIPITATION, FILTRATION, COLORIMETRIC ANALYSIS | HYBRIVET SYSTEMS, INC. (US) | 1996-10-22 | — | — | US | claimed |
| US-5416028-A | Process for testing for substances in liquids | HYBRIVET SYSTEMS, INC. (US) | 1995-05-16 | — | — | US | claimed |
| WO-1995005598-A1 | PROCESS AND APPARATUS FOR TESTING FOR SUBSTANCES IN LIQUIDS | HYBRIVET SYSTEMS, INC. (US) | 1995-02-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589187-B2 | Valve material with combined anti-clotting and anti-calcification properties and preparation method | PROC, F11, SERPINC1 | CA12 551/4885CA1 151/4885CA2 476/4885 |
| US-20120015044-A1 | FORMULATIONS FOR THE TREATMENT OF URUSHIOL-INDUCED CONTACT DERMATITIS | AOC1, AOC3, GPR17 | CA12 1028/4885CA1 1818/4885CA2 2958/4885 |
| US-20230212111-A1 | METHOD FOR RECYCLING TAURINE MOTHER LIQUOR | SLC6A6, SLC6A12, UGT8 | CA12 538/4885CA1 154/4885CA2 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.